دورية أكاديمية
The emergence of SARS-CoV-2 lineages and associated saliva antibody responses among asymptomatic individuals in a large university community.
| العنوان: | The emergence of SARS-CoV-2 lineages and associated saliva antibody responses among asymptomatic individuals in a large university community. |
|---|---|
| المؤلفون: | Merling MR; Department of Microbial Infection & Immunity, The Ohio State University, Columbus, Ohio, United States of America., Williams A; Department of Microbial Infection & Immunity, The Ohio State University, Columbus, Ohio, United States of America.; Infectious Disease Institute, The Ohio State University, Columbus, Ohio, United States of America., Mahfooz NS; Department of Microbial Infection & Immunity, The Ohio State University, Columbus, Ohio, United States of America., Ruane-Foster M; Department of Microbial Infection & Immunity, The Ohio State University, Columbus, Ohio, United States of America., Smith J; Infectious Disease Institute, The Ohio State University, Columbus, Ohio, United States of America., Jahnes J; Infectious Disease Institute, The Ohio State University, Columbus, Ohio, United States of America., Ayers LW; Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America., Bazan JA; Division of Infectious Disease, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America., Norris A; Division of Infectious Disease, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.; Department of Epidemiology, The Ohio State University, Columbus, Ohio, United States of America., Norris Turner A; Division of Infectious Disease, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America., Oglesbee M; Infectious Disease Institute, The Ohio State University, Columbus, Ohio, United States of America., Faith SA; Infectious Disease Institute, The Ohio State University, Columbus, Ohio, United States of America., Quam MB; Department of Epidemiology, The Ohio State University, Columbus, Ohio, United States of America., Robinson RT; Department of Microbial Infection & Immunity, The Ohio State University, Columbus, Ohio, United States of America. |
| المصدر: | PLoS pathogens [PLoS Pathog] 2023 Aug 21; Vol. 19 (8), pp. e1011596. Date of Electronic Publication: 2023 Aug 21 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science, c2005- |
| مواضيع طبية MeSH: | Antibody Formation* , COVID-19*/epidemiology, Aged ; Humans ; SARS-CoV-2 ; Saliva ; Universities ; Breakthrough Infections ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M |
| مستخلص: | SARS-CoV-2 (CoV2) infected, asymptomatic individuals are an important contributor to COVID transmission. CoV2-specific immunoglobulin (Ig)-as generated by the immune system following infection or vaccination-has helped limit CoV2 transmission from asymptomatic individuals to susceptible populations (e.g. elderly). Here, we describe the relationships between COVID incidence and CoV2 lineage, viral load, saliva Ig levels (CoV2-specific IgM, IgA and IgG), and ACE2 binding inhibition capacity in asymptomatic individuals between January 2021 and May 2022. These data were generated as part of a large university COVID monitoring program in Ohio, United States of America, and demonstrate that COVID incidence among asymptomatic individuals occurred in waves which mirrored those in surrounding regions, with saliva CoV2 viral loads becoming progressively higher in our community until vaccine mandates were established. Among the unvaccinated, infection with each CoV2 lineage (pre-Omicron) resulted in saliva Spike-specific IgM, IgA, and IgG responses, the latter increasing significantly post-infection and being more pronounced than N-specific IgG responses. Vaccination resulted in significantly higher Spike-specific IgG levels compared to unvaccinated infected individuals, and uninfected vaccinees' saliva was more capable of inhibiting Spike function. Vaccinees with breakthrough Delta infections had Spike-specific IgG levels comparable to those of uninfected vaccinees; however, their ability to inhibit Spike binding was diminished. These data are consistent with COVID vaccines having achieved hoped-for effects in our community, including the generation of mucosal antibodies that inhibit Spike and lower community viral loads, and suggest breakthrough Delta infections were not due to an absence of vaccine-elicited Ig, but instead limited Spike binding activity in the face of high community viral loads. Competing Interests: The authors have declared that no competing interests exist. (Copyright: © 2023 Merling et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
| References: | Nature. 2020 Aug;584(7821):437-442. (PMID: 32555388) J Clin Invest. 2020 Jun 1;130(6):2757-2765. (PMID: 32254064) Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662) Interface Focus. 2022 Feb 11;12(2):20210072. (PMID: 35261731) Science. 2020 May 29;368(6494):945-946. (PMID: 32385100) Nature. 2021 Nov;599(7883):114-119. (PMID: 34488225) Vaccine. 2014 Apr 11;32(18):2100-8. (PMID: 24560617) PLoS One. 2021 Nov 4;16(11):e0258738. (PMID: 34735480) medRxiv. 2021 Feb 21;:. (PMID: 33594385) S Afr Med J. 1981 Nov 14;60(20):786-8. (PMID: 7029733) Proc Natl Acad Sci U S A. 2022 Oct 18;119(42):e2202871119. (PMID: 36215506) Cell. 2022 Feb 3;185(3):447-456.e11. (PMID: 35026151) EBioMedicine. 2022 Sep;83:104232. (PMID: 35988466) Sci Rep. 2022 Jan 24;12(1):1260. (PMID: 35075213) Lancet Infect Dis. 2022 May;22(5):603-610. (PMID: 35176230) Nature. 2021 Apr;592(7854):438-443. (PMID: 33690265) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Nature. 2022 Feb;602(7898):664-670. (PMID: 35016195) J Autoimmun. 2022 Feb;127:102792. (PMID: 34995958) J Virol. 2013 Nov;87(21):11950-4. (PMID: 23986586) JAMA Netw Open. 2021 Jan 4;4(1):e2035057. (PMID: 33410879) Immunol Rev. 2022 Sep;310(1):27-46. (PMID: 35733376) Nat Microbiol. 2020 Oct;5(10):1185-1191. (PMID: 32908214) Cochrane Database Syst Rev. 2020 Sep 15;9:CD013574. (PMID: 33959956) Nature. 2022 Feb;602(7897):481-486. (PMID: 34942632) NCHS Data Brief. 2022 Dec;(456):1-8. (PMID: 36598387) Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. (PMID: 32747721) Lancet. 2020 Mar 21;395(10228):949-950. (PMID: 32151324) Nature. 2020 Aug;584(7821):353-363. (PMID: 32659783) Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):. (PMID: 34172581) Diagn Microbiol Infect Dis. 2022 May;103(1):115659. (PMID: 35278794) Science. 2022 Nov 11;378(6620):619-627. (PMID: 36264829) N Engl J Med. 2022 Sep 15;387(11):1011-1020. (PMID: 36044620) Nat Hum Behav. 2022 Dec;6(12):1649-1659. (PMID: 36253520) Nature. 2022 Mar;603(7902):679-686. (PMID: 35042229) J Virol. 2013 Sep;87(17):9939-42. (PMID: 23824801) Nature. 2022 Mar;603(7902):706-714. (PMID: 35104837) J Clin Virol. 2022 Jul;152:105170. (PMID: 35525108) Science. 2021 Dec 03;374(6572):1202-1204. (PMID: 34793199) Med. 2021 Mar 12;2(3):263-280.e6. (PMID: 33521748) Nat Med. 2020 Nov;26(11):1691-1693. (PMID: 32929268) Vaccines (Basel). 2022 Feb 07;10(2):. (PMID: 35214710) Sci Rep. 2022 Feb 28;12(1):3313. (PMID: 35228585) JAMA. 2020 Apr 14;323(14):1406-1407. (PMID: 32083643) Nat Med. 2021 Dec;27(12):2108-2110. (PMID: 34728830) J Virol. 2014 Jun;88(12):7045-53. (PMID: 24719424) N Engl J Med. 2020 Mar 5;382(10):929-936. (PMID: 32004427) J Infect Dis. 2014 Jan 15;209(2):236-42. (PMID: 24218506) Science. 2021 Apr 9;372(6538):. (PMID: 33658326) Annu Rev Med. 2022 Jan 27;73:65-80. (PMID: 34437814) N Engl J Med. 2022 Dec 1;387(22):2094-2097. (PMID: 36383452) Elife. 2021 Apr 26;10:. (PMID: 33899740) Science. 2021 May 21;372(6544):815-821. (PMID: 33853970) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) J Infect Dis. 2020 Oct 1;222(9):1462-1467. (PMID: 32798217) J Virol. 2013 Aug;87(16):9379-83. (PMID: 23785207) Cell. 2021 Apr 29;184(9):2348-2361.e6. (PMID: 33730597) MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138. (PMID: 35085223) Nat Commun. 2022 Nov 7;13(1):6706. (PMID: 36344489) Nat Rev Microbiol. 2023 Feb;21(2):112-124. (PMID: 36307535) J Clin Med. 2022 Aug 19;11(16):. (PMID: 36013115) Cell. 2022 Jun 9;185(12):2116-2131.e18. (PMID: 35662412) Microbiol Spectr. 2022 Dec 21;10(6):e0252122. (PMID: 36318040) J Infect Public Health. 2021 Sep;14(9):1201-1205. (PMID: 34416598) Nature. 2021 May;593(7858):270-274. (PMID: 33723411) Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5. (PMID: 24599590) EMBO J. 2020 Oct 15;39(20):e105938. (PMID: 32914439) Nat Rev Immunol. 2020 Jun;20(6):339-341. (PMID: 32317716) Sci Adv. 2022 Nov 16;8(46):eade1860. (PMID: 36399566) ACS Infect Dis. 2021 Jun 11;7(6):1519-1534. (PMID: 33979123) Euro Surveill. 2022 Mar;27(10):. (PMID: 35272744) Nature. 2022 Mar;603(7902):700-705. (PMID: 35104835) Sci Rep. 2022 Oct 27;12(1):18067. (PMID: 36302883) PLoS One. 2020 Dec 9;15(12):e0243597. (PMID: 33296437) Clin Infect Dis. 2023 Feb 8;76(3):e400-e408. (PMID: 35616119) Cell Host Microbe. 2022 Nov 9;30(11):1518-1526.e4. (PMID: 36240764) Nature. 2022 Feb;602(7898):676-681. (PMID: 35016198) Annu Rev Microbiol. 1997;51:151-78. (PMID: 9343347) N Engl J Med. 2020 Mar 5;382(10):970-971. (PMID: 32003551) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) J Biol Chem. 2021 Jul;297(1):100847. (PMID: 34058196) Public Health. 2022 Mar;204:70-75. (PMID: 35176623) J Oral Microbiol. 2013;5:. (PMID: 23487566) Nature. 2021 May;593(7858):266-269. (PMID: 33767447) Front Microbiol. 2022 Apr 01;13:829393. (PMID: 35432272) Nat Microbiol. 2020 Nov;5(11):1403-1407. (PMID: 32669681) Nat Med. 2021 May;27(5):892-903. (PMID: 33767405) Sci Rep. 2022 May 21;12(1):8586. (PMID: 35597780) MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99. (PMID: 33476315) |
| المشرفين على المادة: | 0 (Immunoglobulin A) 0 (Immunoglobulin G) 0 (Immunoglobulin M) |
| تواريخ الأحداث: | Date Created: 20230821 Date Completed: 20230904 Latest Revision: 20231102 |
| رمز التحديث: | 20231102 |
| مُعرف محوري في PubMed: | PMC10470930 |
| DOI: | 10.1371/journal.ppat.1011596 |
| PMID: | 37603565 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!